6.6.12-To expand upon our existing internal informatics support in aptamer development; Base Pair has recently installed an Ion Torrent Personal Genome Machine™ (PGM™) DNA Sequencer.  This investment in operational efficiency will greatly increase sequence analysis capacity, allow for additional exploration of various selection conditions, and expedite delivery of validated aptamers for further application-specific testing by researchers.

“We are excited to add this additional capacity to our process” noted founder and CSO Bill Jackson, “this significant investment will allow us to generate additional information on our aptamers more quickly and provide better service to our customers.  The ability to analyze aptamer selection conditions by sequence in combination with our patent pending multiplex target approach and informatics analysis will allow us to explore more variables in selection and provide a greater variety of potential aptamers to our collaborators.”

Base Pair Biotechnologies has had success with difficult targets, but will also be using the PGM™ to explore prior and current selections in more detail to better understand the resultant aptamers and to improve upon future aptamer development.

About Base Pair Biotechnologies:  Scientists at Base Pair Biotechnologies have been studying aptamers and developing them on a research basis since 2004 and began recently offering these services commercially. With a patent pending multiplexed approach, custom aptamers can be developed to targets of interest at unprecedented speed and cost.  Base Pair Biotechnologies, Inc. is  is a privately held company located in the Medical Center of Houston, Texas.